2,4-Diamino-6-hydroxypyrimidine

Catalog No.S3688 Batch:S368801

Print

Technical Data

Formula

C4H6N4O
Molecular Weight 126.12 CAS No. 56-06-4
Solubility (25°C)* In vitro DMSO 25 mg/mL (198.22 mM)
Water 6 mg/mL (47.57 mM)
Ethanol Insoluble
In vivo (Add solvents to the product individually and in order)
Clear solution
5%DMSO Corn oil
10.0mg/ml Taking the 1 mL working solution as an example, add 50 μL of 200 mg/ml clear DMSO stock solution to 950 μL of corn oil and mix evenly. The mixed solution should be used immediately for optimal results. 
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description 2,4-Diamino-6-hydroxypyrimidine (DAHP) is a specific inhibitor for GTP cyclohydrolase I, the rate-limiting enzyme in de novo pterin synthesis.
Targets
GTP cyclohydrolase I [1]
In vitro 2,4-diamino-6-hydroxy-pyrimidine (DAHP), an inhibitor of GTP cyclohydrolase I, blocks the synthesis of tetrahydrobiopterin (BH4), which is a known cofactor of inducible nitric oxide synthase (iNOS). DAHP is shown to suppress the production of nitric oxide by cytokine-activated fibroblasts, smooth muscle cells or endothelial cells which could be attributed to its function as a cofactor antagonist. DAHP down-regulates the expression of iNOS protein and mRNA in a BH4-independent manner[1].
In vivo DAHP has no effect on brain serotonin levels, presumably due to poor brain penetration. DAHP causes a rapid decrease (T1/2 of less than 12 hr) in the BH4 levels in all tissues examined, except in the brain. The BH4 level returns to within the normal range less than 24 hr after cessation of the administration of DAHP, a finding which suggests that the BH4 level is in a dynamic steady state maintained by rapid local biosynthesis[2].

Protocol (from reference)

Animal Study:[2]
  • Animal Models

    C57BL/6 mice

  • Dosages

    3 g/kg/day

  • Administration

    oral

Selleck's 2,4-Diamino-6-hydroxypyrimidine has been cited by 2 publications

Suppression of GCH1 Sensitizes Ovarian Cancer and Breast Cancer to PARP Inhibitor [ J Oncol, 2023, 2023:1453739] PubMed: 36793373
EGFR-phosphorylated GDH1 harmonizes with RSK2 to drive CREB activation and tumor metastasis in EGFR-activated lung cancer [ Cell Rep, 2022, 41(11):111827] PubMed: 36516759

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.